Literature DB >> 26916982

Effect of Renal Sympathetic Denervation on Specific MicroRNAs as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease.

Oliver Dörr1, Christoph Liebetrau2, Helge Möllmann2, Luise Gaede2, Christian Troidl2, Simone Lankes1, Denise Guckel1, Niklas Boeder1, Sandra Voss2, Timm Bauer1, Christian Hamm1,2, Holger Nef1.   

Abstract

A total of 90 consecutive patients undergoing renal sympathetic denervation (RSD) were included in this study. A significant reduction in office systolic blood pressure (SBP) of 21.1 mm Hg (P<.001) was documented 6 months after RSD. At this time point, circulating concentrations of microRNA (miR)-133a were significantly increased (sevenfold; P<.001) compared with baseline values. Correlation analysis showed a significant relationship between baseline SBP values and SBP reduction (P<.001) as well as between miR-133a baseline levels and the increase in miR-133a expression (P<.001) after the 6-month follow-up. The effect of RSD on miR-133a expression was significantly greater in patients at high risk for hypertensive heart disease. In addition to the effective blood pressure reduction in response to RSD, this study demonstrates an effect of RSD on miR reflecting cardiovascular reverse remodeling processes. Thus, these results provide information on a beneficial effect of RSD on cardiac recovery in patients at high risk for hypertensive heart disease. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26916982      PMCID: PMC8031684          DOI: 10.1111/jch.12797

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  36 in total

1.  Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.

Authors:  Mathias C Brandt; Felix Mahfoud; Sara Reda; Stephan H Schirmer; Erland Erdmann; Michael Böhm; Uta C Hoppe
Journal:  J Am Coll Cardiol       Date:  2012-03-06       Impact factor: 24.094

2.  Circulating microRNAs in patients with coronary artery disease.

Authors:  Stephan Fichtlscherer; Salvatore De Rosa; Henrik Fox; Thomas Schwietz; Ariane Fischer; Christoph Liebetrau; Michael Weber; Christian W Hamm; Tino Röxe; Marga Müller-Ardogan; Angelika Bonauer; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circ Res       Date:  2010-07-01       Impact factor: 17.367

3.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

Review 4.  Role of microRNAs in cardiac remodeling and heart failure.

Authors:  Veli K Topkara; Douglas L Mann
Journal:  Cardiovasc Drugs Ther       Date:  2011-04       Impact factor: 3.727

5.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.

Authors:  David E Kandzari; Deepak L Bhatt; Sandeep Brar; Chandan M Devireddy; Murray Esler; Martin Fahy; John M Flack; Barry T Katzen; Janice Lea; David P Lee; Martin B Leon; Adrian Ma; Joseph Massaro; Laura Mauri; Suzanne Oparil; William W O'Neill; Manesh R Patel; Krishna Rocha-Singh; Paul A Sobotka; Laura Svetkey; Raymond R Townsend; George L Bakris
Journal:  Eur Heart J       Date:  2014-11-16       Impact factor: 29.983

6.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

7.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease.

Authors:  R Querejeta; N Varo; B López; M Larman; E Artiñano; J C Etayo; J L Martínez Ubago; M Gutierrez-Stampa; J I Emparanza; M J Gil; I Monreal; J P Mindán; J Díez
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

Review 8.  Biogenesis and regulation of cardiovascular microRNAs.

Authors:  Johann Bauersachs; Thomas Thum
Journal:  Circ Res       Date:  2011-07-22       Impact factor: 17.367

9.  microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2.

Authors:  Shuguang Dong; Wenhan Ma; Bohan Hao; Fen Hu; Lianhua Yan; Xiaofei Yan; Ya Wang; Zhijian Chen; Zhaohui Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

10.  MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4.

Authors:  Yunhui Cheng; Xiaojun Liu; Shuo Zhang; Ying Lin; Jian Yang; Chunxiang Zhang
Journal:  J Mol Cell Cardiol       Date:  2009-01-27       Impact factor: 5.000

View more
  4 in total

1.  Effect of Renal Sympathetic Denervation on Specific MicroRNAs as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease.

Authors:  Oliver Dörr; Christoph Liebetrau; Helge Möllmann; Luise Gaede; Christian Troidl; Simone Lankes; Denise Guckel; Niklas Boeder; Sandra Voss; Timm Bauer; Christian Hamm; Holger Nef
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-24       Impact factor: 3.738

2.  Renal Denervation Induces Reverse-Remodeling in MicroRNA: Just Blood Pressure Reduction or More?

Authors:  Sebastian Ewen; Ina Zivanovic; Felix Mahfoud
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-24       Impact factor: 3.738

3.  Effects of Cardiac Sympathetic Neurodegeneration and PPARγ Activation on Rhesus Macaque Whole Blood miRNA and mRNA Expression Profiles.

Authors:  Jeanette M Metzger; Mary S Lopez; Jenna K Schmidt; Megan E Murphy; Raghu Vemuganti; Marina E Emborg
Journal:  Biomed Res Int       Date:  2020-05-02       Impact factor: 3.411

Review 4.  MicroRNAs Regulating Renin-Angiotensin-Aldosterone System, Sympathetic Nervous System and Left Ventricular Hypertrophy in Systemic Arterial Hypertension.

Authors:  Alex Cleber Improta-Caria; Marcela Gordilho Aras; Luca Nascimento; Ricardo Augusto Leoni De Sousa; Roque Aras-Júnior; Bruno Solano de Freitas Souza
Journal:  Biomolecules       Date:  2021-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.